The Fund is an actively managed exchange-traded fund (ETF) that seeks to achieve its investment objective by primarily investing in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The Fund invests in exchange-listed equity securities, including common and preferred stock of U.S. and foreign mid-, small- and micro-capitalization companies, and in total return swaps intended to provide exposure to such companies. Under normal circumstances, Fund invests at least 80 percent of its net assets (plus any borrowings for investment purposes) in (i) securities of companies that derive at least 50 percent of their net revenue from or devote 50 percent of their assets to psychedelic drugs and (ii) derivatives that have economic characteristics similar to such securities.